Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation or Bone Marrow Transplantation in Treating Patients With Brain Cancer

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Peripheral stem cell transplantation or bone marrow transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells.

PURPOSE: Phase I trial to study the effectiveness of combining temozolomide, thiotepa, and carboplatin followed by peripheral stem cell transplantation or bone marrow transplantation in treating patients who have brain cancer.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: New York University School of Medicine; NYU Langone Health
• Collaborator: National Cancer Institute (NCI)
• Treatments: Carboplatin; Temozolomide; Thiotepa

Criteria

DISEASE CHARACTERISTICS:

• Diagnosis of one of the following malignant brain tumors:

• Anaplastic astrocytoma

• Glioblastoma multiforme

• Anaplastic oligodendroglioma

• Medulloblastoma

• High-grade ependymoma

• Germ cell tumors

• Pineoblastoma

• Other primitive neuroectodermal tumors

• Recurrent disease or resistant to conventional therapy (e.g., surgery, radiotherapy, or standard chemotherapy)

• No prior myeloablative doses of thiotepa OR

• Newly diagnosed malignant glioma with minimal residual disease after prior radiotherapy

• Minimal residual disease is defined as tumor with maximum diameter of less than 1.5 cm by MRI and no corticosteroid dependency

PATIENT CHARACTERISTICS:

Age:

• Over 1 to under 50

Performance status:

• Karnofsky 70-100% OR

• Lansky 70-100%

Life expectancy:

• More than 12 weeks

Hematopoietic:

• Absolute neutrophil count at least 1,500/mm3

• Platelet count at least 100,000/mm3

• Hemoglobin at least 10 g/dL (transfusion allowed)

Hepatic:

• Bilirubin less than 1.5 times upper limit of normal (ULN)

• SGOT/SGPT less than 2.5 times ULN

• Alkaline phosphatase less than 2.5 times ULN

Renal:

• Creatinine less than 1.5 times ULN

• Creatinine clearance at least 70 mL/min

• BUN less than 1.5 times ULN

Cardiovascular:

• Ejection fraction greater than 50% OR

• Shortening fraction greater than 27%

• No evidence of myocardial ischemia on EKG if over 40 years of age

Other:

• HIV negative

• No AIDS-related illness

• No frequent vomiting or medical condition that would preclude oral medication (e.g., partial bowel obstruction)

• No other malignancy within the past 2 years except surgically cured carcinoma in situ of the cervix or basal cell or squamous cell skin cancer

• Not pregnant or nursing

• Negative pregnancy test

• Fertile patients must use effective contraception

PRIOR CONCURRENT THERAPY:

Biologic therapy:

• At least 2 weeks since prior biologic therapy or immunotherapy

Chemotherapy:

• See Disease Characteristics

• At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin) and recovered

Endocrine therapy:

• See Disease Characteristics

Radiotherapy:

• See Disease Characteristics

• At least 6 weeks since prior radiotherapy and recovered

• At least 6 weeks since prior brachytherapy or radiosurgery

Surgery:

• See Disease Characteristics

• Recovered from prior major surgery